Q1 Earnings Forecast for Longeveron Issued By Zacks Research

Longeveron Inc. (NASDAQ:LGVN) – Research analysts at Zacks Research issued their Q1 2026 EPS estimates for shares of Longeveron in a research note issued on Tuesday, February 17th. Zacks Research analyst B. Sorensen anticipates that the company will post earnings per share of ($1.84) for the quarter. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. Zacks Research also issued estimates for Longeveron’s Q2 2026 earnings at ($2.02) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($4.68) EPS and FY2027 earnings at ($1.65) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Longeveron in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Longeveron currently has a consensus rating of “Hold” and a consensus target price of $6.50.

Longeveron Stock Up 2.7%

Shares of NASDAQ LGVN opened at $0.58 on Friday. The firm’s 50-day moving average price is $0.56 and its two-hundred day moving average price is $0.70. Longeveron has a 52-week low of $0.49 and a 52-week high of $1.92. The stock has a market capitalization of $12.27 million, a P/E ratio of -0.54 and a beta of 0.21.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd purchased a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent quarter. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.